Health TrialsbyHealthPanel

Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL

ConditionDLBCL
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital with Nanjing Medical University

About this trial

Single-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years, male or female;

Histologically confirmed diffuse large B-cell lymphoma (DLBCL);

Relapsed/refractory (R/R) disease；

At least one prior line of therapy containing rituximab;

Disqualifiers

Patient is a candidate for hematopoietic stem cell transplantation.

Prior allogeneic hematopoietic stem cell transplantation.

Primary or secondary central nervous system (CNS) lymphoma or history of CNS lymphoma.

History of severe hypersensitivity or anaphylactic reaction to humanized or murine monoclonal antibodies.

Trial design

Design model

Single group

Treatments tested in this trial

  • EZH2i+GLofit-GemOx

    Drug

    EZH2i+GLofit-GemOx

Treatment groups

46 Participants
are divided into 1 treatment group
Group A: EZH2i+Glofit-GemOxExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Complete response rate, CRR

Time frame
From first dose to end of treatment (assessed up to 12 months)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The First Affiliated Hospital with Nanjing Medical University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: